A Lyme disease vaccine may finally be on the way. Why did it take so long?
Lyme disease cases in Canada rose from 144 in 2009 to 5,809 in 2024, with 7,105 preliminary cases for 2025, according to PHAC data. The article says no human Lyme vaccine is currently approved. Pfizer and Valneva’s PF-07307405 completed Phase 3 with over 70% efficacy after four doses, and Moderna has Phase 2 candidates mRNA-1975 and mRNA-1982.
How this was made
The 30-second read
Why it matters
The article’s core new information is Pfizer and Valneva’s Phase 3 efficacy result for PF-07307405 and Pfizer’s plan to submit to regulators, plus Moderna’s ongoing Phase 2 Lyme mRNA programs.
Market read
Clinical Phase 3 efficacy and the next regulatory step can drive near-term sentiment for Lyme vaccine pipeline holders, while commercialization risks remain.
What to watch
The article notes LYMErix’s historical adverse-reaction coverage and litigation; that legacy could affect payer coverage, physician adoption, and label positioning, limiting near-term commercial upside.
Background
Lyme disease cases in Canada have risen sharply since 2009, and the last human Lyme vaccine (LYMErix) was withdrawn after adverse-reaction coverage and litigation.
Ticker impact
Article says Pfizer and Valneva reported Phase 3 results for PF-07307405 with over 70% efficacy and Pfizer planning regulatory submissions.
Near-term sentiment tailwind for pipeline optimism; magnitude likely limited until submission details and safety/labeling are clearer.
The piece provides a concrete Phase 3 efficacy figure and a next-step (regulatory submissions), but it does not include approval, label, or new safety signals beyond what is already implied.
Article says Moderna is developing two mRNA Lyme vaccines, mRNA-1975 and mRNA-1982, both in Phase 2 trials.
Limited immediate price impact; more relevant for longer-horizon pipeline positioning.
The article discloses ongoing Phase 2 status and vaccine names, but provides no new efficacy/safety results or regulatory milestones for Moderna.
Article states French biotech Valneva co-develops PF-07307405 with Pfizer and reported Phase 3 results with more than 70% efficacy.
Potential positive repricing versus peers on Lyme vaccine development credibility, though still pre-submission/approval.
The article includes a specific Phase 3 efficacy outcome and next-step planning, which is more than background, but it lacks approval or detailed safety/labeling outcomes.
Market effects
Could lift sentiment for infectious-disease vaccine developers and mRNA platform optionality, but the article emphasizes commercialization and adherence challenges.
Primarily US-listed biotech sentiment spillover; Canada case-count context may increase public attention but is not a direct market driver.
Lyme disease burden and vaccine development progress can influence global vaccine R&D expectations, though this is company-specific clinical news.
Counterpoint
Even with Phase 3 efficacy, real-world uptake may be constrained by multi-dose schedules, cost, and potential regulatory requests for additional data.
Key entities
- product_candidatePF-07307405
Pfizer and Valneva co-developed Lyme disease vaccine candidate; Phase 3 reported >70% efficacy after four doses.
- product_candidatemRNA-1975
Moderna Lyme disease mRNA vaccine candidate in Phase 2 trials.
- product_candidatemRNA-1982
Moderna Lyme disease mRNA vaccine candidate in Phase 2 trials.
- historical_vaccineLYMErix
FDA-approved Lyme vaccine in 1998, withdrawn after adverse-reaction coverage and litigation; no new human Lyme vaccines approved since.
